CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated]

Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801‑CX) and Recombinant Mouse CXCL13/BLC/BCA‑1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA‑1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA‑1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801). The ND50 is typically0.3-0.9 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N, CyTOF-ready, ELISA(Cap), Flow
• Clone: 53610
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL13/BLC/BCA-1
  Val23-Arg94
  Accession # O43927
• Specificity: Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL‑8, rhCXCL10, rhCXCL9, rhCXCL12/SDF‑1 alpha, or rhCXCL12/SDF‑1 beta is observed. In Western blots, no cross‑reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.
• Details of Functionality: ActivityAssaywCitation not found None None None None
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CXCL13
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL
  • CyTOF-ready
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • Intracellular Staining by Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 0.3-0.9 ug/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Detection: Human CXCL13/BLC/BCA-1 Biotinylated Antibody (Catalog number BAF801)
  Standard: Recombinant Human CXCL13/BLC/BCA-1 (Catalog number 801-CX)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated]

• ANGIE
• ANGIE2
• B cell-attracting chemokine 1
• B lymphocyte chemoattractant
• BCA1
• BCA-1
• BCA1B-cell chemoattractant
• BCA-1CXC chemokine BLC
• B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1)
• BLC
• BLCSmall-inducible cytokine B13
• BLR1L
• B-lymphocyte chemoattractant
• chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
• chemokine (C-X-C motif) ligand 13
• C-X-C motif chemokine 13
• CXCL13
• SCYB13
• SCYB13B-cell-attracting chemokine 1
• small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Background

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

1. Gunn, M.D. et al. (1998) Nature, 391:799.
2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
3. Forster, R. et al. (1996) Cell 87:1037.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL13/BLC/BCA-1 Antibody (MAB801)(11)

Publications using MAB801

• A Satou, T Tabata, H Miyoshi, K Kohno, Y Suzuki, D Yamashita, K Shimada, T Kawasaki, Y Sato, T Yoshino, K Ohshima, T Takahara, T Tsuzuki, S Nakamura Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases Mod. Pathol., 2019;0(0):. 2019 [PMID: 30952973] (IHC-P, Human)
• R Muto, H Miyoshi, K Sato, T Furuta, H Muta, K Kawamoto, E Yanagida, K Yamada, K Ohshima Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification Cancer Med, 2018;0(0):. 2018 [PMID: 30311404] (IHC, Human)
• DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, A Kiialainen, J Hanhart, C Schill, C Hess, S Savic Prin, M Wiese, D Lardinois, PC Ho, C Klein, V Karanikas, KD Mertz, TN Schumacher, A Zippelius A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade Nat. Med., 2018;0(0):. 2018 [PMID: 29892065] (Flow Cytometry, Human)
• LA Aqrawi, M Ivanchenko, A Björk, JI Ramírez Se, J Imgenberg-, M Kvarnström, P Haselmayer, JL Jensen, G Nordmark, K Chemin, K Skarstein, M Wahren-Her Diminished CXCR5 expression in peripheral blood of patients with Sj�gren&#039;s syndrome may relate to both genotype and salivary gland homing Clin. Exp. Immunol., 2018;0(0):. 2018 [PMID: 29453859] (IHC-P, Human)
• A Asai, Y Tsuchimoto, H Ohama, S Fukunishi, Y Tsuda, M Kobayashi, K Higuchi, F Suzuki Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC Oncoimmunology, 2017;6(4):e1299301. 2017 [PMID: 28507807] (ICC, Human)
• Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol, 2015;16(0):6. 2015 [PMID: 25879435] (Direct ELISA, Human)
• Edwards, Keith R, Goyal, Jaya, Plavina, Tatiana, Czerkowicz, Julie, Goelz, Susan, Ranger, Ann, Cadavid, Diego, Browning, Jeffrey Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS ONE, 2013;8(11):e81007. 2013 [PMID: 24278364] (Immuno-PCR, Human)
• Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kroger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br. J. Cancer, 2008;99(6):930-8. 2008 [PMID: 18781150] (Western Blot, Human)
• Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood, 2007;110(9):3316-25. 2007 [PMID: 17652619] (IHC-P, Human)
• Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54. J. Cell. Physiol., 2006;207(2):364-73. 2006 [PMID: 16331675] (ELISA Development, Human)
• Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp. Gerontol., 2004;39(4):659-65. 2004 [PMID: 15050303] (IHC-P, Human)

Bioinformatics

• Gene Symbol: CXCL13
• Uniprot:
  • O43927()